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Background: To evaluate the insulin receptor isoform mRNA expression status in non-small cell lung cancer
(NSCLC) patients.
Methods: RNA-seq data from 614 NSCLC [355 adenocarcinomas (LUAD) and 259 squamous cell carcinomas (LUSC)]
and 92 normal lung specimens were obtained from The Cancer Genome Atlas (TCGA) to evaluate the mRNA
expression of insulin receptor isoform A (IR-A) and insulin receptor isoform B (IR-B). The differential expression status of
the insulin receptor isoforms in NSCLC patients was confirmed using qRT-PCR assays with lung cancer cDNA
arrays and primary tumor samples.
Results: The mRNA expression levels of IR-B were significantly lower in some NSCLC samples compared to normal lung
specimens, including both LUAD and LUSC. Notably, no IR-B transcripts were detected - only the IR-A isoform was
expressed in 11% of NSCLC patients. This decrease in IR-B expression contributed to an elevated IR-A/IR-B ratio, which
was also associated with lower epithelial-mesenchymal transition gene signatures in NSCLC and longer patient survival
under standard of care in LUSC. In addition to NSCLC, RNA-seq data from TCGA revealed a similar increase in IR-A/IR-B
ratio in many other cancer types, with high prevalence in acute myeloid leukemia, glioblastoma multiforme, and brain
lower grade glioma.
Conclusions: Our results indicate a common reduction of the mRNA expression level of IR-B and an increased IR-A/IR-B
mRNA ratio in NSCLC and other tumor types. The relationship of altered IR-A/IR-B ratios with cancer progression and
patient survival should be prospectively explored in future studies.Background
Lung cancer is the leading cause of cancer death and the
second most diagnosed cancer in both men and women
in the U.S. In 2008, 14% of all cancer diagnoses and 28%
of all cancer deaths were due to lung cancer [1]. Non
small-cell lung cancer (NSCLC) is the most common
type of lung carcinoma and accounts for at least 85% of
all lung cancer cases in the US [2]. Adenocarcinomas* Correspondence: yaoy@medimmune.com; huangj@medimmune.com
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most common subtypes of NSCLC.
Insulin is a crucial growth factor that binds specifically
to the insulin receptor (INSR) and subsequently activates
the PI3K-AKT pathway. This pathway is mainly respon-
sible for mediating the metabolic effects of insulin and
regulating the MAP kinase pathway that influences
important biological processes, such as cell growth and
differentiation [3]. The mature human INSR has two iso-
forms: Insulin receptor isoform A (IR-A) and Insulin re-
ceptor isoform B (IR-B), which form from alternative
splicing of the same primary transcript [4]. The bio-
logical roles of IR-A and IR-B are different. IR-B is atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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while IR-A has high affinities to both insulin and IGF2.
IR-B is responsible for the major metabolic effects of in-
sulin in muscle, liver, and adipose tissues. IR-A promotes
growth and anti-apoptotic effects under physiological
conditions like embryonic development [4,5]. The rela-
tive level of mRNA encoding IR-A and IR-B is regulated
not only in a tissue-specific manner [4,5], but also de-
pends on the stage of cell development and differenti-
ation. For example, in fetal tissues and cancerous cells,
IR-A is the predominant isoform [5].
Dysregulation of the INSR has been reported in mul-
tiple cancers [6-8]. INSR over-expression has also been
associated with lung tumor progression [4,9]. Since dis-
tinct biological roles of IR-A and IR-B exist, it is import-
ant to evaluate the relative abundance of IR-A and IR-B
expression in NSCLC and evaluate their associated prog-
nostic values.
In this study, we analyzed RNA-seq data from 614
NSCLC (355 LUAD and 259 LUSC) and 92 normal lung
tissues from The Cancer Genome Atlas (TCGA). We ob-
served that IR-B mRNA expression was significantly lower
in some NSCLC specimens (both LUAD and LUSC) com-
pared to adjacent normal lung tissues, thereby contribut-
ing to altered IR-A/IR-B mRNA ratio in this disease.
Intriguingly, we observed that patients with higher IR-A/
IR-B mRNA ratio generally showed upregulated oxidative
phosphorylation pathway, lower epithelial-mesenchymal
transition (EMT) gene expression signatures in NSCLC
and exhibited longer survival under standard of care in
LUSC. Additionally, the down regulation of IR-B and
higher IR-A/IR-B mRNA ratio was also displayed in other
18 tumor types. Overall, our results suggest that the IR-A/
IR-B mRNA ratio may serve as a prognostic maker to
guide clinical treatment decisions of LUSC; and character-
izing the specific relationship of this biomarker with prog-
nosis and treatment response might also be valuable for
other cancer indications.
Methods
Molecular profiling and data processing
Normalized expression data of the genes and transcript iso-
forms for NSCLC were downloaded from Level 3 RNA-seq
data of TCGA (https://tcga-data.nci.nih.gov/tcga/dataAc-
cessMatrix.htm) dated March, 2013. The data include both
LUAD and LUSC. TCGA collection includes 614 treatment
naive NSCLC tumor samples (355 LUAD and 259 LUSC)
and 92 adjacent normal lung tissues. All cancer specimens
are comprised of at least 75% tumor tissue.
Bioinformatics analysis of insulin receptor isoforms using
RNA-seq data
The normalized isoform expression files and exon ex-
pression files generated by TGCA provide expressioninformation of INSR isoforms. IR-A and IR-B mRNA
expression levels were retrieved from normalized iso-
form expression files. The expression levels of IR-A and
IR-B mRNA were compared between normal lung tis-
sues and tissues from LUSC and LUAD. The mRNA ex-
pression ratio of IR-A and IR-B was calculated using
RNA-Seq by Expectation-Maximization (RSEM) nor-
malized read counts (https://wiki.nci.nih.gov/display/
TCGA/RNASeq); for 0 read counts and the others as
well, evaluation of the distribution justified a pseudo
count of 0.1. The IR-A/IR-B ratios between LUSC,
LUAD and adjacent normal tissue were compared using
Wilcoxon-Mann–Whitney two group (two-tailed) test.
Since IR-A differs from IR-B by the exclusion of exon
11, we also calculated IR-A/IR-B ratios using the exon
10, 11, and 12 normalized expression files from TCGA
to quantify the expression levels of IR-A and IR-B for
the quality assurance.Experimental confirmation of INSR isoform expression
status in NSCLC
Experimental confirmation of INSR isoform expression
status was performed in two independent panels of
NSCLC specimens. Panel 1 consists of five lung cancer
cDNA arrays (HLRT101, HLRT102, HLRT103, HLRT104,
and HLRT105) purchased from OriGene Technologies
(Rockville, MD). The arrays contained cDNAs from 50
normal lung tissue (38 unique donors), 84 adenocarcin-
oma and 60 squamous-cell carcinoma samples. The tumor
stage ranged from Stage IA to IV. The tumor samples
were comprised of 35-95% tumor. Panel 2 included pri-
mary, fresh frozen, treatment naïve NSCLC tumors from
24 patients and adjacent normal tissues from 12 of the 24
patients collected from the Shanghai Chest Hospital. Each
tumor sample was comprised of greater than 70% tumor.
All patients provided written informed consent before
study-related procedures were performed.
The primers and probes of TaqMan gene expression as-
says for IR-A and IR-B and methods were described in de-
tail in Huang et al. [10]. The reference genes ACTB
(Hs99999903_m1), GAPDH (Hs99999905_m1) and GUSB
(AssyID: Hs99999908_m1) were purchased from Life
Technologies.
cDNA samples in panel 1 were preamplified using
TaqMan Pre-Amp Master Mix (Life Technologies, CA),
according to the manufacturer’s instructions. Reactions
contained 5 μL of cDNA, 10 μL of Pre-Amp Master
Mix, and 5 μL of 0.2× gene expression assay mix (com-
prised of all primer/probes to be assayed) at a final reac-
tion volume of 20 μL. Reactions were cycled with the
recommended 14-cycle program and then diluted 1:5
with TE buffer. Preamplified cDNA was used immedi-
ately or stored at −20°C until processed. For PCR, the
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previously described [10].
The number of replicates and the composition of the
samples varied depending on the particular experiment
but were never less than triplicate. Average Cycle
Threshold (Ct) values were used to determine sensitivity
and specificity of the designed probes. Ct values were
extracted from each assay with the SDS v2.0 software
tool (Applied Biosystems, CA). The average Ct values of
all available reference gene assays within a sample were
utilized for calculation of ΔCt.
MRNA for panel 2 samples was isolated using
Ambion Recover All Total Nucleic Acid Isolation kit
(Life Technologies). RNA quality was assessed on an
Agilent 2100 Bioanalyzer using the RNA 6000 Nano
LabChip® (Agilent technologies, CA). RNA purity and
concentration were determined spectrophotometrically
(260/280 > 1.9). 2ug RNA were reverse transcribed to
cDNA following the manufacturer’s protocol. The same
volume of cDNA for each sample was evaluated by
qPCR.
All samples were normalized to the average expression
levels of the 3 housekeeping genes: ACTB, GAPDH and
UBC. The relative expression level was represented by -ΔCt,
where -ΔCt =− [(Ct of a gene of interest) - (Average Ct of 3
housekeeping genes)].
The relative difference in expression level between
tumor and normal lung samples was represented by
-ΔCt, and the IR-A/IR-B expression ratio was presented
as the ΔCt differential (IR-A ΔCt – IR-B ΔCt). To deter-
mine over-expression of genes in lung cancer relative to
normal lung, we calculated fold changes values using the
formula 2 -ΔΔCt, where ΔΔCt for a gene of interest is
defined as: (ΔCt lung cancer sample - mean ΔCt of
all normal samples). A cutoff of 2-fold was used to
determine over-expression.
Molecular characterization of NSCLC tumors with higher
IR-A/IR-B ratio
Based on the distribution of IR-A/IR-B ratio, the tumor
samples were divided into two groups: high IR-A/IR-B ra-
tio (HIR) and low IR-A/IR-B ratio group (LIR). The genes
with significant differential expression (fold change > 2,
Benjamini-Hochberg adjusted p-value < 0.05) were identi-
fied between the two groups, in order to identify gene ex-
pression signatures associated with a high IR-A/IR-B ratio.
Clinical characterization of squamous cell carcinoma
(LUSC) patients with higher IR-A/IR-B ratio
Clinical information for LUSC samples were downloaded
from TCGA (Level 2 Biolab data). The clinical features
of patients with HIR were compared to patients with
LIR. The survival analyses were conducted using R
(http://www.r-project.org). The median overall survival(OS) was determined using the Kaplan-Meier method
from the R package survival. The Cox regression model
was applied to assess IR-A/IR-B ratio on the prognostic
value of OS, which was adjusted by patient covariates
including gender, smoking history, age at initial patho-
logic diagnosis, tumor stage, and treatment with chemo-
therapy. P values < 0.05 were considered statistically
significant.
Results
Higher IR-A/IR-B mRNA ratio is observed in NSCLC
patients using a large patient population from TCGA
To evaluate the expression of IR-A and IR-B mRNAs in
NSCLC, we utilized the large RNA-seq database from
TCGA. As shown in Figure 1A, the median normalized
expression of IR-B is statistically significantly lower in
LUSC (P < 0.0001) but not in LUAD (P = 0.064) as com-
pared to normal lung. Notably, a small fraction of
NSCLC samples (11%) do not express IR-B. The median
normalized mRNA expression of IR-A is also signifi-
cantly higher in LUAD (P = 0.001) and LUSC (P = 0.043)
compared to normal lung tissues.
The mRNA ratio for IR-A and IR-B was additionally
assessed for both LUAD and LUSC, and results are
shown in Figure 1B. The IR-A/IR-B mRNA ratio is sta-
tistically significantly higher in LUAD (P < 0.001) and
LUSC (P < 0.001) compared to normal lung tissues. IR-B
mRNA expression was drastically down-regulated in a
fraction of NSCLC tumor samples, as shown by the bi-
modal distribution of the IR-A/IR-B ratio observed in
these samples (Figure 1B). To confirm the results, we
also calculated the IR-A/IR-B mRNA ratio using the nor-
malized exon expression values for exons 10, 11, and 12
of INSR from TCGA and similar results were observed
(data not shown).
We also assessed the mRNA expression levels of
IGF1R and found that 12 out of 144 (8%) NSCLC sam-
ples have >2 fold IGF1R mRNA expression than the
normal lung samples in the panel 1. We explored rela-
tionships between IGF1R and INSR isoforms and un-
covered no clear relationships in our test panels or
TGCA data sets.
TaqMan qRT-PCR confirms the decreased mRNA level of
IR-B and increased IR-A/IR-B mRNA ratio in NSCLC
The TaqMan qRT-PCR measurements of mRNA expres-
sion levels of IR-A in NSCLC using cDNA array (Panel 1;
see Methods) and NSCLC primary tissue (Panel 2; see
Methods) are shown in Figure 2A and Figure 2B. A
two-sample test indicated that the mRNA levels for IR-A
were significantly lower in LUSC specimens (P = 0.0007)
compared to normal lung specimens from cDNA arrays
(Figure 2A), with a similar trend observed in primary
tumor specimens (Figure 2B). The mRNA levels for IR-A
Figure 1 Transcript abundance of insulin receptor isoforms in LUAD and LUSC profiled by TCGA RNA-seq data. A) Log2-transformed and
normalized read count of IR-A and IR-B receptor isoforms in LUAD (n = 355), LUSC (n = 259) and adjacent normal tissue (n = 92) and B) the
corresponding distribution of log2-transformed IR-A/IR-B mRNA ratio. Asterisks indicate statistically significant differences (* = P < 0.05;
** = P < 0.01; *** = P < 0.001).
Jiang et al. BMC Cancer 2014, 14:131 Page 4 of 10
http://www.biomedcentral.com/1471-2407/14/131were not significantly different between normal lung and
LUAD specimens (P = 0.050) in either sample set. The
mRNA levels for IR-B were significantly lower in LUAD
(P < 0.001) and LUSC primary tumor specimens compar-
ing to normal lung tissues (P < 0.001) run on cDNA array
(Figure 2). Although there are differences in IR-A mRNA
expression in LUAD and LUSC versus normal in TCGA
data compared with results from panel 1 and 2, the overallFigure 2 TaqMan qRT-PCR confirmation of relative mRNA Expression
arrays. TaqMan gene expression assays determined the relative mRNA exp
of IR-A and IR-B were normalized to the average expression levels of 3 hou
levels of IR-A and IR-B are represented by -ΔCt, where -ΔCt = − [(Ct of a ge
represent the mean -ΔCt ± 95% CI within a particular gene target and sam
tumor samples. Asterisks indicate statistically significant differences (* = P <magnitude of changes in IR-A expression are rather mod-
est compared to those in IR-B. Differences in sample
size and content of the tumor samples could contribute to
the minor variability in IR-A expression observed between
these datasets.
IR-A/IR-B mRNA ratios in tumors from panel 1 and
panel 2 were normalized to the average IR-A/IR-B
mRNA ratio from normal lung specimens and are shownLevels for IR-A and IR-B in NSCLC primary tumors run on cDNA
ression levels of IR-A and IR-B. For each sample, the expression levels
sekeeping genes (ACTB, GAPDH and UBC). The relative expression
ne of interest) - (Average Ct of 3 housekeeping genes)]. The error bars
ple-type combination. (A): data from cDNA array, (B) data from primary
0.05; ** = P < 0.01; *** = P < 0.001).
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nificantly higher in LUAD samples (P < 0.001) and LUSC
samples (P < 0.001), compared to normal lung speci-
mens. The increase in IR-A/IR-B mRNA ratio and de-
creased IR-B mRNA expression observed in primary and
cDNA array samples is consistent with what was origin-
ally observed using RNA-seq data from TCGA.
Stratification of patients into IR-A/IR-B mRNA ratio high
and low groups and identification of the differentially
expressed genes associated with EMT
To better characterize the molecular landscape of tumors
with altered IR-A/IR-B mRNA ratios, we used TCGA data
to identify differentially expressed genes in tumors that
are associated with high IR-A/IR-B mRNA ratio (HIR). To
do this, we evaluated the distribution of the IR-A/IR-B
mRNA ratio in NSCLC tumors and normal lung speci-
mens, revealing a bimodal distribution in both sample
types (Figure 4A). While most normal samples (88 out of
92) have IR-A/IR-B ratio equal to approximately 1 [log2
(mean ± sd) = 0.10 ± 0.84], the distribution in NSCLC
patients is shifted, associated with an increased ratio in
this cancer type (Figure 4A). Using these distributions, weFigure 3 TaqMan qRT-PCR confirmation of IR-A/IR-B mRNA
ratio in NSCLC primary tumors using cDNA array. The IR-A/IR-B
mRNA ratio was assessed by determining ΔCt differentials of IR-A
and IR-B in lung cancer and normal lung samples. The ΔCt differential
(IR-B ΔCt – IR-A ΔCt) values were calculated for each specimen utilizing
the within-specimen reference gene panel (average Ct) and normalized
to the average of the normal lung samples. The error bars represent
the mean -ΔCt ± 95% CI within a particular gene target and
sample-type combination. Dotted line indicates average levels of
IR-A/IR-B ratios in normal lung tissues.identified log2(8) (i.e., 3, P < 0.001) as the cutoff value,
which is at least 3 times the standard deviation from the
mean (0.1), to classify the tumor specimens into two
groups - high IR-A/IR-B mRNA ratio and low IR-A/IR-B
mRNA ratio (LIR). In the subsequent analysis of RNA-seq
data, 114 differentially expressed genes shared between
LUAD and LUSC were identified (see Methods). Gene set
enrichment analysis (GSEA) indicated that the down-
regulated genes were significantly enriched with EMT
genes (Figure 4C) and genes involved in ECM-receptor
interaction (Figure 4B), which have been reported to be
significantly increased in invasive NSCLC cancer types
(Byers LA, 2013). GSEA also revealed that genes up-
regulated in HIR specimens are enriched with genes in-
volved in the mitochondria oxidative phosphorylation
pathway (Figure 4D).
At the molecular level, LUSC have been previously di-
vided into four different subtypes (primitive: prolifera-
tion; classical: xenobiotic metabolism; secretory: immune
response; basal: cell adhesion) which have clinical im-
portance [9]. We utilized this subtype classification gen-
erated by Wilkerson et al., to analyze the TCGA data
and compare the IR-A/IR-B mRNA ratio among the dif-
ferent subclasses. No significant differences in IR-A/IR-B
mRNA ratio were observed (data not shown) among
these four subtypes.
HIR is associated with a better clinical outcome under
standard of care
The clinical features and survival information of LUSC pa-
tients were also utilized from TCGA portal. We evaluated
the survival experience associated with IR-A/IR-B mRNA
ratio after adjusting for gender, smoking history, age at ini-
tial pathologic diagnosis, tumor stage, and chemotherapy
treatment. In univariate analysis, no statistically significant
association between IR-A/IR-B mRNA ratio and these
clinical features was observed. However, the Cox propor-
tional hazards model indicated that patients with HIR
have better survival outcome (hazard ratio = 0.46; 95% CI
[0.23, 0.89]; P = 0.022; Figure 5), which is also consistent
with the association of HIR with a decreased EMT/less in-
vasive phenotype.
Survey of the IR-A/IR-B mRNA ratio in multiple tumor types
To examine whether increased IR-A/IR-B mRNA ratios
are a common event occurring in other cancer types, we
used TCGA RNA-seq exon and junction level data to as-
sess INSR isoform expression status in tumor and normal
adjacent tissues from a panel of cancer types including
acute myeloid leukemia (LAML), bladder urothelial car-
cinoma (BLCA), glioblastoma multiforme (GMB), brain
lower grade glioma (LGG), breast invasive carcinoma
(BRCA), colon adenocarcinoma (COAD), rectum ade-
nocarcinoma (READ), head and neck squamous cell
Figure 4 IR-A/IR-B mRNA ratio in NSCLC and the differentially expressed genes associated with the ratio of IR-A/IR-B mRNA. A.
Distribution of the IR-A/IR-B mRNA ratio among the NSCLC and the adjacent normal lung specimens. According to the distribution of IR-A/IR-B
mRNA ratio in the adjacent normal lung (the top panel), log2(8) (i.e., 3) was selected as the cutoff value to stratify the subjects into two groups:
high IR-A/IR-B ratio (HIR) and low IR-A/IR-B ratio (LIR). B-D. Gene set enrichment analysis (GSEA) of the differentially expressed genes in NSCLC
patients with HIR and LIR. GSEA enrichment plots showing that ECM (B) and EMT (C) signaling were down-regulated (p < 0.001, respectively) in
LUSC samples with HIR. Additionally, the oxidative phosphorylation pathway was highly enriched in the LUSC samples with HIR (D).
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ovarian serous cystadenocarcinoma (OV), thyroid carcin-
oma (THCA), uterine corpus endometrioid carcinoma
(UCEC), kidney chromophobe (KICH), kidney renal clear
cell carcinoma (KIRC), and kidney renal papillary cell car-
cinoma (KIRP). The results are shown in Figure 6. A sig-
nificantly increased IR-A/IR-B mRNA ratio (i.e., >3) was
observed in BRCA, COAD, KIRC, KIRP, liver hepatocellu-
lar carcinoma (LIHC), and UCEC compared to adjacent
normal tissues. It is worth noting that the prevalence of
HIR in brain tumors (GMB and LGG) and LAML are
greater than 93% (Table 1).Discussion
Preclinical studies suggest that signaling via the INSR
isoforms IR-A and IR-B may be of critical importance
in NSCLC [11,12]. After the failures of two large
randomized phase III anti-IGF1R trials in NSCLC,
(Figitumumab [13], hR1507 [13,14]), IR-A signaling
has been postulated as one of the major mediators
of resistance to anti-IGF1R therapy [11,15]. However,
due to technical difficulties, a key measurement to
address this issue, the mRNA expression status of in-
sulin receptor isoforms in primary NSCLC was largely
unknown.
Figure 5 Kaplan-Meier plot comparing survival in LUSC
patients with HIR versus LIR. Overall survival was adjusted by
patient covariates including gender, smoking history, age at initial
pathologic diagnosis, tumor stage, and treatment with
chemotherapy. A P < 0.05 achieved in the analysis was considered to
be statistically significant. The LUSC patients with HIR (dotted line)
show a significant difference in survival compared to those with low
ratio (dashed line) (hazard ratio, 0.457; 95% CI [0.23, 0.89]; P = 0.022).
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data generated from well-characterized primary NSCLC
tumors by TCGA to evaluate mRNA expression of the
splice variants IR-A and IR-B. This analysis was ex-
tended to include additional NSCLC samples beyond
those available from TCGA, as well as additional tumor
types. In summary, in all NSCLC datasets evaluated, we
observed down-regulation of IR-B mRNA expression
with an associated increase in the IR-A/IR-B mRNA ra-
tio in a subpopulation of patients. We also found a sig-
nificant increase in the prevalence of patients with HIR
in BRCA, COAD, KIRC, KIRP, LIHC, and UCEC com-
pared to normal tissues, with the prevalence of HIR in
brain tumors (both GMB and LGG) greater than 93%.
These findings are important because they suggest that
many cancer types experience alterations in the INSR
pathway, which may be important for disease pathogen-
esis. Although we observed differences in the mRNA ex-
pression levels of IR-A in the TCGA dataset compared
with our internal data, it may be due to overall differ-
ences in sensitivity and specificity between the platforms
for IR-A quantitation and/or heterogeneity within tumor
samples between our test panels and TGCA. Additional
work will need to be done to get a fuller understanding
of the role of IR-A and IR-B expression in NSCLC and
other cancer types.
Given the role of the INSR in glucose metabolism, we
postulate that the change of IR-A/IR-B mRNA ratio intissues could be associated with differences in metabol-
ism in tumor tissue compared to normal tissue. It has
been shown previously that glucose metabolism in can-
cer cells is altered from normal oxidative phosphoryl-
ation to glycolysis [16], such that tumor cells take up
much more glucose and mainly process it through aer-
obic glycolysis rather than oxidative phosphorylation i.e.
the ‘Warburg effect’, [17]. This metabolic switch empha-
sizes the production of intermediates necessary for
tumor growth and division and has been shown to be
regulated by oncogenes and tumor suppressor genes in a
number of key cancer growth pathways [18]. Alterations
in the IR-A/IR-B mRNA ratio in NSCLC might be re-
lated to the Warburg effect in tumors. The down regula-
tion of IR-B could be a negative feedback from cancer
cells in response to the high glucose intake, thereby
decreasing the Warburg effect in cancer cells. This is
suggested by our observations that cancers with higher
IR-A/IR-B mRNA ratio have higher mRNA expression
levels of genes involved in oxidative phosphorylation, as
well as a less cancerous phenotype and greater survival
in LUSC. At the same time, since the IRA has high affin-
ity to IGF2, the higher IR-A/IR-B mRNA ratio could
push cells to depend more on IGF2 signaling through
IR-A [19], resulting in increased proliferation signaling.
The concentration of IGF2 in the microenvironment of
a particular tumor type may be critical to influence the
effect of the increased IR-A/IR-B mRNA ratio. For ex-
ample, for tumor types without high IGF2, increased IR-
A/IR-B mRNA ratio may be of benefit to the patients
due to the lack of proliferation signaling through IR-A.
To further understand the molecular characteristics
associated with the changes in the IR-A/IR-B mRNA ra-
tio in NSCLC, we analyzed the differentially expressed
genes between the HIR and LIR groups. We found in
both LUAD and LUSC, genes involved in extracellular
matrix (ECM) interactions such as collagen type I, V, VI,
X; integrin, alpha 8, 11; and fibronectin type III domain
containing 1 are significantly down regulated in patients
with HIR (P < 0.01). The enzymes involved in ECM re-
modeling such as metallopeptidases cartilage oligomeric
matrix protein, and matrix-remodeling associated 5 are
also significantly down regulated (P < 0.01). All these
genes are part of EMT signatures [20], where EMT is a
process by which epithelial cells lose their cell polarity
and cell-cell adhesion while gaining migratory and inva-
sive properties to become mesenchymal cells [21,22]. In
NSCLC cancer specifically, EMT has been associated
with EGF receptor inhibitor resistance and worse clinical
outcome [20]. ECM/integrin signaling has also been
demonstrated to provide a survival advantage to various
cancer cell types against chemotherapeutic drugs and
antibody therapy [23]. The association of HIR with de-
creased EMT signatures described in this manuscript
Figure 6 Distribution of the IR-A/IR-B mRNA ratio in 20 types of cancer evaluated using TCGA RNA-seq database. According to the
distribution of IR-A/IR-B mRNA ratio in the adjacent normal, 8 (=23) is selected as the cutoff value to defined the high IR-A/IR-B ratio group (HIR). Acute
Myeloid Leukemia (LAML), Bladder Urothelial Carcinoma (BLCA), Glioblastoma multiforme (GMB), Brain Lower Grade Glioma (LGG), Breast invasive
carcinoma (BRCA), Colon adenocarcinoma (COAD), Rectum adenocarcinoma (READ) Head and Neck Squamous Cell Carcinoma (HNSC), Prostate
adenocarcinoma (PRAD), Ovarian serous cystadenocarcinoma (OV), Thyroid carcinoma (THCA), Uterine Corpus Endometrioid Carcinoma (UCEC),
Kidney Chromophobe (KICH), Kidney renal clear cell carcinoma (KIRC), and Kidney renal papillary cell carcinoma (KIRP) were analyzed for
expression levels of IR-A and IR-B and grouped according to HIR or LIR. The numbers of patients in each group are indicated in the table, as well as
the fraction of patients with HIR. The P value column indicates a statistically significant difference in the prevalence of HIR in a particular tumor
type compared to the associated normal tissue using a binomial proportions test.
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static lung cancers, which is consistent with the ob-
served association between HIR and increased survival.
Based on our previous data in breast cancer, theseresults were somewhat unexpected; however, they reveal
that the relevance of the IR-A/IR-B mRNA ratio as a
cancer biomarker has to be evaluated for each tumor
type. The complex relationship between altered INSR
Table 1 Statistic summary of the IR-A/IR-B mRNA ratio in 20 types of cancer
Disease Normal Tumor
HIR LIR HIR fraction HIR LIR HIR fraction P value*
Bladder Urothelial Carcinoma (BLCA) 2 14 0.13 16 106 0.13 0.5
Breast invasive carcinoma (BRCA) 1 106 0.01 140 709 0.16 0
Cervical squamous cell carcinoma and endocervica adenocarcinoma (CESC) 0 2 0 51 65 0.44 0.3
Colon adenocarcinoma (COAD) 3 15 0.17 90 103 0.47 0.014
Glioblastoma multiforme (GBM) NA NA NA 157 12 0.93 NA
Brain Lower Grade Glioma (LGG) NA NA NA 215 5 0.98 NA
Head and Neck squamous cell carcinoma (HNSC) 2 35 0.05 17 286 0.06 0.5
Kidney Chromophobe (KICH) 0 25 0 6 60 0.09 0.139
Kidney renal clear cell carcinoma (KIRC) 0 71 0 27 453 0.06 0.04
Kidney renal papillary cell carcinoma (KIRP) 0 25 0 12 64 0.16 0.039
Acute Myeloid Leukemia (LAML) NA NA NA 173 0 1 NA
Liver hepatocellular carcinoma (LIHC) 0 36 0 9 60 0.13 0.029
Lung adenocarcinoma (LUAD] 4 53 0.07 45 310 0.13 0.158
Lung squamous cell carcinoma (LUSC) 0 35 0 42 218 0.16 0.01
Ovarian serous cystadenocarcinoma (OV) N/A N/A N/A 48 218 0.18 NA
Prostate adenocarcinoma (PRAD) 2 42 0.05 12 164 0.07 0.418
Rectum adenocarcinoma (READ) 0 3 0 23 29 0.44 0.182
Skin Cutaneous Melanoma (SKCM) NA NA NA 87 180 0.33 NA
Thyroid carcinoma (THCA) 3 53 0.05 41 373 0.1 0.197
0 11 0 102 268 0.28 0.046
The numbers of samples classified as high IR-A/IR-B mRNA ratio (HIR) and low IR-A/IR-B mRNA ratio (LIR) in each tumor type as well as the statistic significances
(P value) of the prevalence of HIR samples in each tumor type compared with that in the corresponded normal tissues are indicated in table.
*Bold font indicates statistically significant results i.e., p-value < 0.05.
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challenges associated with targeting the IGF1R pathway
in NSCLC and other cancers. It is also important to note
that there are currently no methods available to quantify
the protein level of IRA and IRB. These data could be
helpful for subsequent evaluation of the clinical utility of
IRA/IRB mRNA ratio in caner.
Conclusion
HIR was commonly observed in multiple solid tumors
surveyed in this study, although the functional import-
ance of these increased ratios likely differ between these
tumor types. Since both IR-A and IR-B are regulated by
insulin, IGF1 and IGF2 through autocrine and/or para-
crine mechanisms, the microenvironment of the cancer
site may also contribute to the relationship of HIR with
clinical prognosis and patient survival. Therefore, the
exact impact of the increase in IR-A/IR-B mRNA ratio
in the clinical course of specific cancer types needs to be
carefully evaluated before initiation of any intervention,
especially those targeting the IGF pathway. Blocking al-
tered metabolic signaling pathways through the IGF axis
could benefit patients of one type of cancer but may be
less likely to benefit patients with other cancer types.Accordingly, the knowledge that the IR-A/IR-B mRNA
ratio is altered across multiple cancer indications is the
foundation for continued efforts to characterize the ef-
fect of this alteration on cancer progression and thera-
peutic response in order to achieve the most benefit.
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